Loading stock data…
AVR
$6.36+0.21 (+3.41%)
Market ClosedLast close May 1
Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Anteris Technologies Global Corp. in the Healthcare sector is trading at $6.36. The stock is currently near its 52-week high of $6.95, remaining 29.3% above its 200-day moving average. Technical signals show neutral RSI of 54 and bullish MACD crossover, explaining why AVR maintains its current momentum and trend strength. The Whystock Score of 70/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 54) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$6.36
Potential Upside
5%
Whystock Fair Value$6.68
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus4 analysts
Mean target$15.75+147.6%
Range$15.00 – $17.00
Fundamentals
Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$537.69M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.55
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-2257.54%
Volume
Today's trading volume
1.01M
Recent News
Anteris secures US Medicare coverage for PARADIGM Trial as DurAVR study advances
Anteris Technologies Pty Ltd (ASX:AVR, NASDAQ:AVR) has secured US Medicare reimbursement eligibility for eligible procedures in its global pivotal PARADIGM Trial, a prospective, randomised controlled study designed to evaluate the safety and effectiveness of Anteris’ DurAVR® Transcatheter Heart...
A new valve, a new playbook: How Anteris is trying to reshape a $10B heart market
Cardiovascular disease may be one of medicine’s oldest battlegrounds, but some of its most important technologies are still evolving — and not always as quickly as patients, and investors, might expect. Nowhere is that more evident than in transcatheter aortic valve replacement (TAVR), a...
Anteris Technologies Global CEO Touts DurAVR Redesign, Durability Claims and TAVR Market Strategy
Anteris Technologies Global (NASDAQ:AVR) CEO and founder Wayne Paterson discussed the company’s DurAVR transcatheter aortic valve replacement (TAVR) program, recent clinical visibility, and the company’s approach to market development during a conversation that touched on product design, tissue scie
Anteris Technologies Global Highlights DurAVR TAVR Data, PARADIGM Pivotal Trial Plans at TD Cowen Conference
Anteris Technologies Global (NASDAQ:AVR) Chief Executive Officer Wayne Paterson outlined the company’s DurAVR transcatheter aortic valve replacement (TAVR) program during a fireside chat at TD Cowen’s conference in Boston, focusing on the platform’s design rationale, early clinical experience, and t
Anteris reports US$77.8m 2025 net operating cash outflow as PARADIGM trial gets underway
Anteris Technologies Pty Ltd (ASX:AVR, NASDAQ:AVR) has reported a net operating cash outflow of US$77.8 million for the year ended December 31, 2025, as it increased spending across clinical, regulatory and manufacturing work to support its global pivotal PARADIGM trial. The structural heart...